Haemophilia A

Haemophilia is a serious, inherited bleeding disorder in which a person’s blood does not clot properly, in severe cases leading to uncontrolled bleeding, either spontaneously or after minor trauma.

Medical care for haemophilia A, the most well-known inherited bleeding disorder, is often restricted in developing countries. Left untreated, bleeds can lead to irreversible joint damage and intracranial bleeds, and potentially cause brain development problems which may be life-threatening. Roche is working closely with multiple partners to provide consistent and predictable access to preventative and on-demand treatment for bleeding disorders, for people in locations that need it most.

For more than 20 years, Roche has been innovating and delivering medicines for people with diseases of the blood. With the rise of novel therapies within haemophilia, we are working closely with all corners of the global haemophilia community – through our efforts to help improve the provision of treatments for those who need it most; through our dedication towards supporting patients at all stages of their haemophilia journey; and ultimately helping to transform the way haemophilia is treated and managed.

We are collaborating with the WFH to provide a novel prophylactic treatment to as many as 1,000 people with haemophilia A over five years in locations where there is little or no access to haemophilia treatment. In addition, Roche contributes to the WFH Humanitarian Aid Program integrated care development training, with funding to ensure local infrastructure and medical expertise are available to optimise and appropriately use the donated product.

By working toward a shared vision of Treatment for All, the WFH and all of its partners, including Roche, aim to address gaps in healthcare and bring innovative treatment solutions to patients living with haemophilia.